2019
Burden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy
Ambrosy AP, Stevens SR, Al‐Khalidi H, Rouleau JL, Bouabdallaoui N, Carson PE, Adlbrecht C, Cleland JGF, Dabrowski R, Golba KS, Pina IL, Sueta CA, Roy A, Sopko G, Bonow RO, Velazquez EJ, Investigators O. Burden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. European Journal Of Heart Failure 2019, 21: 373-381. PMID: 30698316, PMCID: PMC6818499, DOI: 10.1002/ejhf.1404.Peer-Reviewed Original ResearchConceptsCharlson co-morbidity indexCCI scoreSurgical revascularizationEjection fractionMedical therapySTICH trialHeart failureIschemic cardiomyopathyKansas City Cardiomyopathy QuestionnaireCo-morbidity indexCoronary artery bypassCo-morbid conditionsHealth-related qualityCoronary artery diseaseRisk of deathProportional hazards modelYears of ageTreatment effectsGreater functional limitationsArtery bypassCause mortalityIschemic etiologyArtery diseaseWalk testBaseline confounders
2012
Race and gender variation in the QT interval and its association with mortality in patients with coronary artery disease: Results from the Duke Databank for Cardiovascular Disease (DDCD)
Williams ES, Thomas KL, Broderick S, Shaw LK, Velazquez EJ, Al-Khatib SM, Daubert JP. Race and gender variation in the QT interval and its association with mortality in patients with coronary artery disease: Results from the Duke Databank for Cardiovascular Disease (DDCD). American Heart Journal 2012, 164: 434-441. PMID: 22980312, DOI: 10.1016/j.ahj.2012.05.024.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseCause mortalityArtery diseaseProlonged QTcRisk factorsQT intervalMortality riskLow glomerular filtration rateHigher diastolic blood pressureNative coronary artery stenosisCardiac risk factorsLow ejection fractionDiastolic blood pressureGlomerular filtration rateCoronary artery stenosisRisk of deathCardiac catheterizationCardiac eventsDuke DatabankBlood pressureEjection fractionQTc intervalQTc prolongationArtery stenosisBaseline electrocardiogram
2011
Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both
Shah AM, Hung CL, Shin SH, Skali H, Verma A, Ghali JK, Køber L, Velazquez EJ, Rouleau JL, McMurray JJ, Pfeffer MA, Solomon SD. Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. American Heart Journal 2011, 162: 685-691. PMID: 21982661, DOI: 10.1016/j.ahj.2011.07.015.Peer-Reviewed Original ResearchConceptsLV mass indexRisk of deathRelative wall thicknessDiabetic patientsEjection fractionMass indexHigh riskBaseline LV mass indexLeft ventricular systolic dysfunctionHigher LV mass indexHeart failure post-myocardial infarctionVALIANT Echo studyAtrial volume indexVentricular systolic dysfunctionAge-adjusted modelsQuantitative echocardiographic analysisPost-myocardial infarctionHF hospitalizationLong-term elevationNondiabetic patientsConcentric remodelingSystolic dysfunctionAtrial enlargementHeart failureClinical outcomesPredictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction
Thune JJ, Signorovitch JE, Kober L, McMurray JJ, Swedberg K, Rouleau J, Maggioni A, Velazquez E, Califf R, Pfeffer MA, Solomon SD. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. European Journal Of Heart Failure 2011, 13: 148-153. PMID: 21037250, DOI: 10.1093/eurjhf/hfq194.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedCaptoprilCause of DeathConfidence IntervalsDrug Therapy, CombinationFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPredictive Value of TestsPrognosisProportional Hazards ModelsRecurrenceRisk AssessmentSeverity of Illness IndexSex FactorsSurvival AnalysisTetrazolesTime FactorsValineValsartanVentricular Dysfunction, LeftConceptsRecurrent myocardial infarctionFirst myocardial infarctionRisk of deathLeft ventricular dysfunctionMyocardial infarctionVentricular dysfunctionHeart failurePrognostic impactOne-year mortalityGlomerular filtration rateEarly reinfarctionLate reinfarctionTrial cohortUnstable anginaProlong survivalMedian timeMI survivorsFiltration ratePatientsContemporary managementContemporary treatmentInfarctionMortalityReinfarctionDeath
2010
The inter‐relationship of diabetes and left ventricular systolic function on outcome after high‐risk myocardial infarction
Shah AM, Uno H, Køber L, Velazquez EJ, Maggioni AP, MacDonald MR, Petrie MC, McMurray JJ, Califf RM, Pfeffer MA, Solomon SD. The inter‐relationship of diabetes and left ventricular systolic function on outcome after high‐risk myocardial infarction. European Journal Of Heart Failure 2010, 12: 1229-1237. PMID: 20965879, DOI: 10.1093/eurjhf/hfq179.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionRecurrent myocardial infarctionHF hospitalizationRisk of deathMyocardial infarctionCause mortalityHigh riskSpectrum of LVEFHigh-risk post-MI patientsBaseline left ventricular ejection fractionHigher left ventricular ejection fractionHigh-risk myocardial infarctionAcute Myocardial Infarction trialCox proportional hazards modelPost-MI populationHeart failure hospitalizationMyocardial Infarction trialNon-diabetic patientsVentricular systolic functionVentricular ejection fractionPost-MI patientsAcute myocardial infarctionPotent risk factorProportional hazards modelFailure hospitalizationAtrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial
Nilsson KR, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober L, Granger CB, Lewis EF, McMurray JJ, Califf RM, Velazquez EJ. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart 2010, 96: 838. PMID: 20406769, DOI: 10.1136/hrt.2009.180182.Peer-Reviewed Original ResearchConceptsRhythm control strategyAcute Myocardial Infarction trialMyocardial Infarction trialAtrial fibrillationMyocardial infarctionRate control strategyEarly mortalityAnti-arrhythmic drug therapyTreatment of AFPeri-infarct periodIncidence of strokeManagement of patientsRisk of deathLate mortalityPatient populationDrug therapyCox modelPatientsMortalityInfarctionStrokeValsartanTrialsDeathDaysMechanical Dyssynchrony After Myocardial Infarction in Patients With Left Ventricular Dysfunction, Heart Failure, or Both
Shin SH, Hung CL, Uno H, Hassanein AH, Verma A, Bourgoun M, Køber L, Ghali JK, Velazquez EJ, Califf RM, Pfeffer MA, Solomon SD. Mechanical Dyssynchrony After Myocardial Infarction in Patients With Left Ventricular Dysfunction, Heart Failure, or Both. Circulation 2010, 121: 1096-1103. PMID: 20176989, DOI: 10.1161/circulationaha.109.863795.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalog-Digital ConversionAngiotensin II Type 1 Receptor BlockersDeathDisease ProgressionFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedMotionMyocardial ContractionMyocardial InfarctionPrognosisProportional Hazards ModelsStress, MechanicalTetrazolesUltrasonographyValineValsartanVentricular Dysfunction, LeftVideo RecordingConceptsSD of timeLeft ventricular dysfunctionHeart failureMyocardial infarctionMechanical dyssynchronyVentricular dysfunctionIndependent predictorsPost-myocardial infarction prognosisPeak velocityAdverse cardiovascular outcomesMultivariate Cox modelRisk of deathLeft ventricular segmentsMeasures of dyssynchronyVelocity vector imagingCardiovascular outcomesEchocardiographic variablesVentricular synchronyVentricular dyssynchronyClinical outcomesEchocardiography studyRisk factorsContractile patternsVentricular segmentsCox model
2009
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial
Moukarbel GV, Signorovitch JE, Pfeffer MA, McMurray JJ, White HD, Maggioni AP, Velazquez EJ, Califf RM, Scheiman JM, Solomon SD. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. European Heart Journal 2009, 30: 2226-2232. PMID: 19556260, DOI: 10.1093/eurheartj/ehp256.Peer-Reviewed Original ResearchConceptsRisk factorsGastrointestinal bleedingGI bleedingWorse New York Heart Association classNew York Heart Association classAcute Myocardial Infarction trialPost-myocardial infarction patientsAdditional antiplatelet drugsProfound risk factorRate of GIAdjusted hazard ratioDual antiplatelet therapyMultivariable Cox modelMyocardial Infarction trialDual antiplatelet agentsLeft ventricular dysfunctionGlomerular filtration rateHigh-risk survivorsUse of antiplateletPost-MI patientsRisk of deathPotential risk factorsNon-white racePresent secondary analysisOccurrence of GIUsefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial)
Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA. Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial). The American Journal Of Cardiology 2009, 104: 151-157. PMID: 19576338, DOI: 10.1016/j.amjcard.2009.03.020.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenergic beta-AntagonistsAgedAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionProspective StudiesRisk AssessmentRisk FactorsSurvival AnalysisTetrazolesTreatment OutcomeValineValsartanConceptsBeta blockersHeart failureMyocardial infarctionBaseline characteristicsAcute Myocardial Infarction trialAngiotensin receptor blocker valsartanCombination of valsartanNonfatal cardiovascular eventsAngiotensin receptor blockersBeta-blocker useMyocardial Infarction trialVentricular systolic dysfunctionHigh-risk patientsRisk of deathSignificant survival advantageCardiovascular eventsSystolic dysfunctionVentricular dysfunctionVentricular functionSurvival advantageLower riskPatientsMortality rateBlockersValsartanChronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP, Investigators F. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal Of Heart Failure 2009, 11: 292-298. PMID: 19176539, PMCID: PMC2645058, DOI: 10.1093/eurjhf/hfp001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAtherosclerosisCause of DeathConfidence IntervalsDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionOdds RatioPrognosisProportional Hazards ModelsProspective StudiesPulmonary Disease, Chronic ObstructiveSurvival RateTetrazolesTime FactorsValineValsartanConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAcute Myocardial Infarction trialMyocardial Infarction trialPulmonary diseaseAcute myocardial infarctionAtherosclerotic eventsMyocardial infarctionIndependent predictorsCV outcomesHazard ratioNon-fatal clinical eventsNon-CV deathAdjusted hazard ratioMajor cardiovascular eventsHigh-risk patientsRisk of deathProportional hazards modelMode of deathMedian followCardiovascular eventsCause mortalityAirway diseaseMultivariate adjustmentUnadjusted risk
2008
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study
Lewis EF, Velazquez EJ, Solomon SD, Hellkamp AS, McMurray JJ, Mathias J, Rouleau JL, Maggioni AP, Swedberg K, Kober L, White H, Dalby AJ, Francis GS, Zannad F, Califf RM, Pfeffer MA. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. European Heart Journal 2008, 29: 748-756. PMID: 18308687, DOI: 10.1093/eurheartj/ehn062.Peer-Reviewed Original ResearchConceptsHeart failure hospitalizationMyocardial infarctionFailure hospitalizationHigh-risk acute myocardial infarctionFirst heart failure hospitalizationHigh-risk myocardial infarctionStable post-MI patientsIndex myocardial infarctionRecurrent myocardial infarctionPrior myocardial infarctionLong-term survivorsPost-MI patientsRisk of deathAcute myocardial infarctionOnset of HFAntecedent diabetesTime-dependent fashionVALIANT studyCardiovascular deathInitial hospitalizationVentricular dysfunctionMost patientsRenal functionIndependent predictorsPrognostic factors
2006
Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction☆
Køber L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz R, Maggioni AP, Mareev V, Opolski G, Van de Werf F, Zannad F, Ertl G, Solomon SD, Zelenkofske S, Rouleau J, Leimberger JD, Califf RM. Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction☆. European Journal Of Heart Failure 2006, 8: 591-598. PMID: 16507350, DOI: 10.1016/j.ejheart.2005.11.007.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAngiotensin II Type 1 Receptor BlockersAtrial FibrillationCaptoprilCardiac Output, LowFemaleHumansMaleMiddle AgedMyocardial InfarctionOutcome Assessment, Health CarePrognosisProportional Hazards ModelsRisk AssessmentRisk FactorsSurvival AnalysisTetrazolesTime FactorsValineValsartanVentricular Dysfunction, LeftConceptsAcute myocardial infarctionCurrent atrial fibrillationPrior atrial fibrillationHeart failureAtrial fibrillationRisk of deathMyocardial infarctionCV eventsGreater long-term mortalityMajor CV eventsPrior heart failureAdverse CV eventsMajor cardiovascular eventsVentricular systolic dysfunctionLong-term mortalityHR of deathMajor risk indicatorsCardiovascular eventsSystolic dysfunctionVentricular dysfunctionPrimary outcomeVALIANT trialPatientsLVSDInfarction
2004
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. New England Journal Of Medicine 2004, 351: 1285-1295. PMID: 15385655, DOI: 10.1056/nejmoa041365.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilCardiovascular DiseasesChronic DiseaseCreatinineDouble-Blind MethodDrug Therapy, CombinationFemaleGlomerular Filtration RateHumansKidney DiseasesMaleMiddle AgedMyocardial InfarctionProportional Hazards ModelsRisk FactorsSurvival RateTetrazolesValineValsartanConceptsGlomerular filtration rateAcute myocardial infarctionMyocardial infarctionCardiovascular outcomesHeart failureRisk factorsAcute Myocardial Infarction trialFour-component ModificationNonfatal cardiovascular outcomesMyocardial Infarction trialUse of aspirinComposite cardiovascular eventsComposite end pointRenal Disease equationCongestive heart failureMild renal diseaseRisk of deathCoronary revascularization proceduresMajor risk factorSerum creatinine measurementsBody surface areaCardiovascular causesKillip classRenal eventsCardiovascular complicationsNewly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction
Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O’Connor C, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction. Circulation 2004, 110: 1572-1578. PMID: 15364810, DOI: 10.1161/01.cir.0000142047.28024.f2.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilCohort StudiesComorbidityDiabetes ComplicationsDiabetes MellitusDrug Therapy, CombinationFemaleFollow-Up StudiesHeart FailureHumansLife TablesMaleMedical RecordsMiddle AgedMulticenter Studies as TopicMyocardial InfarctionProportional Hazards ModelsRandomized Controlled Trials as TopicRiskStrokeTetrazolesTime FactorsTreatment OutcomeValineValsartanVentricular Dysfunction, LeftConceptsAcute myocardial infarctionMyocardial infarctionCardiovascular eventsDiabetes mellitusAdverse outcomesAcute Myocardial Infarction trialPoor long-term outcomesMajor cardiovascular eventsMyocardial Infarction trialHigh-risk patientsRisk of deathLong-term outcomesRisk of mortalityBaseline characteristicsDiabetic statusComorbid conditionsMetabolic abnormalitiesPrior diagnosisPoor prognosisNew diagnosisDiabetesPatientsMellitusOutcomesInfarction